One plane of thought for me when considering biotechs I pigeonhole them by their candidates; from most predictable to least predictable and least dramatic to most dramatic returns:
Generic drugs US drugs under development that are already approved in non-US markets Candidates similar to already-approved drugs Unique candidates with properties not in already-approved drugs